Registrations for the certificate are now closed.
Contact us if you would like to follow specific lectures.

Benefit Corporation: a path to affordable gene therapies?

With the growing number of efficient gene therapies on the market, now is the time to take actions to ensure reasonable pricing of gene therapy products.

In the article published in Nature Medicine, Alain Fischer, Mathias Dewatripont and Michel Goldman propose to incentivize gene therapy companies to adopt a status of certified B corporations that translates their corporate social responsibility into concrete commitments.